|
|
|
|
||
Re: Demand Elasticity and Afrezza's PricingGood analysis but slightly off. MNKD needs to improve the Label first and foremost. Insurance companies (with the influence of the BIG 3) will not give Afrezza better coverage until MNKD can prove it is superior to existing therapies. Now maybe the STUDIES that are underway will help (Levin & Dexcom) but for now Priority #1 is to get a better label. I hope it can be done without doing an extensive Study but I'm afraid that's the case. We shall see. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
16967 | Re: Demand Elasticity and Afrezza's Pricing | tocentsworth | 2 | 2/15/2020 3:57:11 PM |